Cargando…

Measurable residual disease in chronic lymphocytic leukemia

Measurable residual disease (MRD) is defined as the presence of residual cancer cells after treatment in patients with clinically undetectable disease, who would otherwise be considered in complete remission. It is a highly sensitive parameter which indicates the disease burden and predicts survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benintende, Giulia, Pozzo, Federico, Innocenti, Idanna, Autore, Francesco, Fresa, Alberto, D’Arena, Giovanni, Gattei, Valter, Laurenti, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971803/ https://www.ncbi.nlm.nih.gov/pubmed/36865804 http://dx.doi.org/10.3389/fonc.2023.1112616

Ejemplares similares

Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study
por: Benintende, Giulia, et al.
Publicado: (2022)

Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review
por: Autore, Francesco, et al.
Publicado: (2021)

PB1933: TREATMENT SEQUENCING AND OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED AT FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS: A THIRTY-YEAR SINGLE-CENTER EXPERIENCE.
por: Fresa, Alberto, et al.
Publicado: (2023)

Role of microRNAs in Chronic Lymphocytic Leukemia
por: Autore, Francesco, et al.
Publicado: (2023)

Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review
por: Fresa, Alberto, et al.
Publicado: (2021)

Immune Response to Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia (CLL): An Experience from Two Italian Centres
por: Innocenti, Idanna, et al.
Publicado: (2022)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units
por: Salvi, Gianfranco, et al.
Publicado: (2015)

The Use of Monoclonal Antibodies in the Treatment of Autoimmune Complications of Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2013)

VEGF and IL-6 Correlation in POEMS: a Potential Upcoming Marker of Active Disease and Early Autologous BMT Response
por: Tomasso, Annamaria, et al.
Publicado: (2022)

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
por: Autore, Francesco, et al.
Publicado: (2020)

PB1872: ANTIBODY RESPONSES AFTER COVID-19 VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA, EITHER TREATED OR NAÏVE. A MONOCENTRIC EXPERIENCE.
por: Innocenti, I., et al.
Publicado: (2022)

Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience
por: Autore, Francesco, et al.
Publicado: (2021)

SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
por: Pozzo, Federico, et al.
Publicado: (2020)

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance
por: D’Arena, Giovanni, et al.
Publicado: (2020)

Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia
por: Del Poeta, Giovanni, et al.
Publicado: (2020)

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
por: Bulian, Pietro, et al.
Publicado: (2012)

Case report: Hematologic malignancies concomitant diagnosis of hairy cell leukemia and chronic lymphocytic leukemia: A rare association
por: Valvano, Luciana, et al.
Publicado: (2022)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
por: Cohen, Jared A., et al.
Publicado: (2020)

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
por: Wang, Jiguang, et al.
Publicado: (2014)

Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience
por: Laurenti, Luca, et al.
Publicado: (2013)

Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?
por: Sora, Federica, et al.
Publicado: (2021)

Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021
por: Bacigalupo, Andrea, et al.
Publicado: (2021)

SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation
por: Sorà, Federica, et al.
Publicado: (2020)

P1305: NEPA VERSUS ONDANSETRON FOR THE PREVENTION OF CINV IN PATIENTS WITH MULTIPLE MYELOMA OR LYMPHOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. A MONOCENTRIC REAL-LIFE EXPERIENCE.
por: Innocenti, Idanna, et al.
Publicado: (2023)

Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review
por: Autore, Francesco, et al.
Publicado: (2018)

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12
por: Autore, Francesco, et al.
Publicado: (2019)

P1509: CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS INFECTIONS HAD IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTRE SEIFEM STUDY
por: Autore, Francesco, et al.
Publicado: (2023)

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy
por: Cohen, Jared A., et al.
Publicado: (2020)

Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond
por: Pozzo, Federico, et al.
Publicado: (2022)

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
por: D'Arena, Giovanni, et al.
Publicado: (2013)

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia
por: Pagotto, Sara, et al.
Publicado: (2019)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019)

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance
por: Dal-Bo, Michele, et al.
Publicado: (2009)

Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role
por: D'Arena, Giovanni, et al.
Publicado: (2016)

Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience
por: Autore, Francesco, et al.
Publicado: (2022)

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
por: Arruga, Francesca, et al.
Publicado: (2023)

The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials
por: Fisher, A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h6b2f328b97a7kd3pijpdndtdi